Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525871 | 1.00 | SOS1 (0.43) | SOS1MEN1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL30014661 | 1.00 | SOS1 (0.43) | SOS1MEN1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL28880437 | 0.83 | TRPA1 (0.44) | SOS1 | |
| SCHEMBL29945762 | 0.83 | TRPA1 (0.44) | SOS1 | |
| SCHEMBL23563604 | 0.83 | TRPA1 (0.44) | SOS1 | |
| SCHEMBL23525827 | 0.82 | SOS1 (0.41) | SOS1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL23525828 | 0.82 | SOS1 (0.41) | SOS1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL30014414 | 0.82 | SOS1 (0.41) | SOS1SMN1; SMN2MAPK1ALDH1A1LMNA | |
| SCHEMBL25632950 | 0.81 | SOS1 (0.42) | SOS1SMN1; SMN2MAPK1ALDH1A1IMPDH2 | |
| SCHEMBL23526320 | 0.78 | HTT (0.46) | SOS1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | SOS1 1/4885MEN1 214/4885KMT2A 3283/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | SOS1 1/4885MEN1 184/4885KMT2A 3302/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | SOS1 1/4885MEN1 184/4885KMT2A 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.